Trial Profile
A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Utomilumab (Primary) ; Carboplatin; Etoposide phosphate; Ifosfamide
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 24 Jul 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 24 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Dec 2023.
- 31 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.